Peyvandi F, Jayandharan G, Chandy M, Srivastava A, Nakaya S M, Johnson M J, Thompson A R, Goodeve A, Garagiola I, Lavoretano S, Menegatti M, Palla R, Spreafico M, Tagliabue L, Asselta R, Duga S, Mannucci P M
Department of Medicine and Medical Specialities, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Luigi Villa Foundation, University of Milan, Milan, Italy.
Haemophilia. 2006 Jul;12 Suppl 3:82-9. doi: 10.1111/j.1365-2516.2006.01263.x.
Inherited deficiencies of plasma proteins involved in blood coagulation generally lead to lifelong bleeding disorders, whose severity is inversely proportional to the degree of factor deficiency. Haemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX). Together with von Willebrand's disease, a defect of primary haemostasis, these X-linked disorders include 95% to 97% of all the inherited deficiencies of coagulation factors. The remaining defects, generally transmitted as autosomal recessive traits, are rare with prevalence of the presumably homozygous forms in the general population of 1:500,000 for FVII deficiency and 1 in 2 million for prothrombin (FII) and factor XIII (FXIII) deficiency. Molecular characterization, carrier detection and prenatal diagnosis remain the key steps for the prevention of the birth of children affected by coagulation disorders in developing countries, where patients with these deficiencies rarely live beyond childhood and where management is still largely inadequate. These characterizations are possible by direct or indirect genetic analysis of genes involved in these diseases, and the choice of the strategy depends on the effective available budget and facilities to achieve a large benefit. In countries with more advanced molecular facilities and higher budget resources, the most appropriate choice in general is a direct strategy for mutation detection. However, in countries with limited facilities and low budget resources, carrier detection and prenatal diagnosis are usually performed by linkage analysis with genetic markers. This article reviews the genetic diagnosis of haemophilia, genetics and inhibitor development, genetics of von Willebrand's disease and of rare bleeding disorders.
参与血液凝固的血浆蛋白遗传性缺乏通常会导致终身出血性疾病,其严重程度与因子缺乏程度成反比。甲型和乙型血友病,呈X连锁隐性遗传,是由凝血因子VIII(FVIII)和因子IX(FIX)缺乏或功能障碍引起的最常见的遗传性出血性疾病。与作为初级止血缺陷的血管性血友病一起,这些X连锁疾病占所有遗传性凝血因子缺乏症的95%至97%。其余缺陷通常以常染色体隐性性状遗传,较为罕见,在一般人群中,FVII缺乏的纯合形式患病率约为1:500,000,凝血酶原(FII)和因子XIII(FXIII)缺乏的患病率为1:2,000,000。在发展中国家,分子特征分析、携带者检测和产前诊断仍然是预防凝血障碍患儿出生的关键步骤,在这些国家,这些缺陷患者很少能活过童年,而且管理仍然很不完善。通过对这些疾病相关基因进行直接或间接遗传分析可以实现这些特征分析,策略的选择取决于有效可用预算和设施,以实现最大效益。在拥有更先进分子设施和更高预算资源的国家,一般最恰当的选择是直接检测突变的策略。然而,在设施有限和预算资源较低的国家,携带者检测和产前诊断通常通过与遗传标记的连锁分析来进行。本文综述了血友病的基因诊断、遗传学和抑制剂的发展、血管性血友病及罕见出血性疾病的遗传学。